ALS Ltd.

ALS Ltd.

19.71
AUD
-0.66
(-3.24%)
0.64EPS
31.65P/E
10.56BMarket Cap
Nov 23Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
Revenue per Share
3.74
3.33
2.98
2.52
2.89
3.42
3.79
3.65
4.37
4.71
5.08
6.19
6.85
Basic EPS, GAAP
0.38
-0.41
-0.53
0.16
0.1
0.32
0.26
0.36
0.39
0.6
0.03
0.53
0.66
Free Cash Flow per Basic Share
0.38
0.32
0.21
0.23
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.25
0.18
0.16
0.12
0.16
0.2
0.23
0.15
0.27
0.37
0.39
0.37
0.4
Book Value per Share
3.36
2.81
2.22
2.33
2.27
2.25
2.28
2.22
2.03
2.82
2.44
2.64
3.35
Tangible Book Value per Share
-0.01
-0.08
0.39
0.38
0.26
0.1
-0.13
-0.14
-0.44
-0.1
-0.67
-0.84
0.18
Basic Weighted Avg Shares
402
427
458
504
501
487
483
482
482
484
484
484
485
Sales/Revenue/Turnover
1,503
1,422
1,365
1,272
1,447
1,665
1,832
1,761
2,109
2,279
2,462
2,999
3,320
Operating Margin (%)
15.81
13.84
10.7
13.29
14.32
15.46
15.13
15.12
15.1
18.95
16.32
14.15
15.91
Depreciation Expense
83
96
102
69
71
75
133
133
139
152
174
234
253
Net Income, GAAP
154
-174
-241
82
52
154
128
173
191
291
13
256
319
Effective Tax Rate (%)
27.4
- -
- -
29.4
41.59
27.1
48.38
29.94
31.94
29.28
87.63
28.62
29.27
Profit Margin (%)
10.27
-12.27
-17.63
6.41
3.58
9.24
6.98
9.8
9.03
12.78
0.52
8.54
9.6
Working Capital
252
397
500
473
386
64
350
233
-639
141
177
392
314
LT Debt
750
935
749
701
696
514
1,569
927
1,269
1,269
1,554
1,929
1,455
Total Equity
1,419
1,228
1,128
1,185
1,122
1,103
1,111
1,080
994
1,378
1,197
1,294
1,705
Return on Invested Capital (%)
8.98
- -
- -
6.28
4.48
10.06
3.9
7.27
8.43
10.55
1.65
9.64
10.99
Return on Capital (%)
9.09
- -
- -
5.37
3.61
9.59
5.97
7.81
8.54
11.18
0.61
9.6
10.79
Return on Common Equity (%)
12.9
-13.3
-20.62
7.11
4.53
13.96
11.65
15.91
18.57
24.79
1.01
20.8
21.39

Capital Structure

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

AUD

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

AUD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.34%
11.49%
31.75%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
192.27%
375.62%
24.4%
Sales/Revenue/Turnover
9.65%
13.67%
10.69%
Total Cash Common Dividend
14.79%
25.75%
9.32%

Semi-annual Revenue

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
2,462
2025
- -
- -
2,999
2026
- -
- -
3,320

Semi-annual Earnings Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.03
2025
- -
- -
0.53
2026
- -
- -
0.66

Semi-annual Dividends Per Share

AUD

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.39
2025
- -
- -
0.37
2026
- -
- -
0.4

Company Description

CEO
Malcolm Deane
Full Time Employees
23,342
Sector
Commercial services
Industry
Miscellaneous commercial services
Address
25 King Street Brisbane QLD Australia 4006
IPO Date
Jul 18, 1952
Business
ALS Limited (ASX:ALQ) provides professional technical services, primarily testing, measurement, and inspection solutions to the mining, environmental, life sciences, energy, and industrial sectors worldwide. The company operates through three main divisions: Commodities, offering geochemistry, metallurgy, coal testing, mine site services, and inspection for the global mining industry; Life Sciences, delivering environmental monitoring, food and pharmaceutical quality assurance, electronics testing, animal health, and consumer products analysis; and Industrial, providing asset care, tribology, diagnostic testing, and engineering services for energy, resources, transportation, and infrastructure. ALS maintains approximately 350 laboratory and operational sites across Africa, Asia Pacific, Europe, the Middle East, North Africa, and the United States, serving diverse clients including mining companies, pharmaceutical firms, food producers, and industrial operators. Founded as Australian Laboratory Services in 1974 and acquired in 1981 by Campbell Brothers (now ALS Limited, listed on the ASX since 1952), the company is headquartered in Brisbane, Australia. In 2024, ALS completed the acquisition of Europe-based Wessling Holding GmbH & Co. KG, adding around 1,200 employees and expanding its Life Sciences footprint, particularly in environmental, food, and pharmaceutical testing markets in Germany and France; it also acquired Northeast USA-based York Analytical Laboratories to bolster its North American operations.

Company News

  • ALS Limited (CPBLF) Shareholder/Analyst Call Transcript

  • ALS Limited (CPBLF) Q4 2026 Earnings Call Transcript

  • ALS (OTCMKTS:CPBLF) & Ipsos (OTCMKTS:IPSOF) Financial Survey

  • ALS Ltd delivers $3 billion revenue in FY25, unveils $350 million equity raise